- 133.6k views
Yes! We can end TB! World Tuberculosis Day
Tuberculosis is a leading cause of death worldwide, with an estimated 1.5 million deaths in 2020, and is particularly prevalent in low- and middle-income countries. The DOTS (Directly Observed Treatment, Short-Course) regimen is the recommended treatment for tuberculosis (TB) by the World Health Organization (WHO). It is a six-month course of four first-line drugs: Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide. The DOTS regimen is also cost-effective and feasible to implement in resource-limited settings, making it a critical component of global efforts to end TB.
About the Speaker
Dr. Padmanesan Narasimhan
Digital Health Roster of Experts at World Health Organization
Dr. Padma Narasimhan was awarded the UNSW-University International Postgraduate Scholarship for a PhD at the School. . He is the Deputy Director of the WHO Collaborating Centre for Digital Health at UNSW and is listed as a Roster of Experts in the newly formed WHO Department of Digital Health. His research work has been published widely in leading local and international journals and he currently serves as the section editor for the prestigious PLoS Digital Health journal.
Upcoming Case Discussions
Preparing your Practice for Adoption of AI
Preparing Your Practice for Adoption of AI" involves building a foundation of digital literacy, data readiness, and ethical awareness among clinicians and staff. Successful integration starts with identifying key workflows where AI can enhance efficiency, accuracy, or patient outcomes. It’s essential to choose tools that align with your practice’s goals while ensuring transparency, security, and compliance. Training, change management, and continuous evaluation are critical to fostering trust and long-term adoption. Ultimately, AI should support—not replace—the human touch in medicine.
AI in Medicine: Challenges and Opportunities
AI in Medicine: Challenges and Opportunities explores the transformative potential of artificial intelligence in improving diagnostics, treatment planning, and healthcare delivery. The session highlights how AI can enhance clinical accuracy, streamline workflows, and support personalized medicine. At the same time, it addresses key challenges such as data privacy, algorithm bias, and the need for regulatory oversight. Real-world applications and case studies illustrate both the promise and the pitfalls of integrating AI into clinical practice. This session aims to equip healthcare professionals with a balanced view of how AI can complement human expertise in medicine.
Ayurvedic Path to Parkinson’s Relief: Research Based Perspective
Ayurvedic Path to Parkinson's Relief: A Research-Based Perspective explores how ancient Ayurvedic principles can complement modern approaches in managing Parkinson's disease. Drawing from recent clinical studies and traditional wisdom, this session delves into the use of herbal formulations, Panchakarma therapies, and lifestyle modifications to alleviate motor and non-motor symptoms. It highlights the neuroprotective potential of key herbs like Mucuna pruriens and Ashwagandha. Backed by evidence and expert insights, the session aims to bridge traditional healing with modern neurological care for holistic patient outcomes.
Congenital Uterine Anomalies
Congenital uterine anomalies are structural abnormalities of the uterus resulting from improper fusion, canalization, or resorption of the Müllerian ducts during fetal development. These anomalies include septate, bicornuate, unicornuate, and didelphys uterus, among others. They can be asymptomatic or associated with infertility, recurrent pregnancy loss, preterm birth, or abnormal menstruation. Diagnosis is typically made using imaging modalities like ultrasound, MRI, or hysterosalpingography. Treatment depends on the type and severity of the anomaly, with surgical correction such as hysteroscopic septum resection often indicated in symptomatic cases. Early detection is crucial for optimizing reproductive outcomes and guiding appropriate management strategies.
Approach to severe hyperkalemia in ICU
Approach to Severe Hyperkalemia in the ICU focuses on rapid identification and targeted intervention to prevent life-threatening complications. The session outlines key steps including ECG monitoring, membrane stabilization with calcium gluconate, intracellular potassium shift using insulin-dextrose and beta-agonists, and potassium elimination via diuretics or dialysis. It emphasizes prioritizing reversible causes like renal failure or medication-induced hyperkalemia. Real-world ICU scenarios and evidence-based protocols will guide clinicians in managing this critical electrolyte emergency effectively.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr. Padmanesan Narasimhan's Talks on Assimilate
- 24th-March-2023, TIME : 2:00PM - 3:00PM
- 0
Tuberculosis is a leading cause of death worldwide, with an estimated 1.5 million deaths in 2020, and is particularly prevalent in low- and middle-income countries. The DOTS (Directly Observed Treatment, Short-Course) regimen is the recommended treatment for tuberculosis (TB) by the World Health Organization (WHO). It is a six-month course of four first-line drugs: Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide. The DOTS regimen is also cost-effective and feasible to implement in resource-limited settings, making it a critical component of global efforts to end TB.
- 24th-March-2023, TIME : 2:00PM - 3:00PM
- 0
Tuberculosis is a leading cause of death worldwide, with an estimated 1.5 million deaths in 2020, and is particularly prevalent in low- and middle-income countries. The DOTS (Directly Observed Treatment, Short-Course) regimen is the recommended treatment for tuberculosis (TB) by the World Health Organization (WHO). It is a six-month course of four first-line drugs: Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide. The DOTS regimen is also cost-effective and feasible to implement in resource-limited settings, making it a critical component of global efforts to end TB.